Sinopia Biosciences Publishes Preclinical Data in Science Translational Medicine Supporting SB-0110, a Novel PKA-II Modulator, for Parkinson's Disease

A preclinical study in highly translatable non-human primate models found that selective PKA-II modulation combined with levodopa improved motor benefit while reducing dyskinesia. The results are encouraging for Parkinson’s symptom control, but no clinical or company-specific quantitative outcomes were provided, limiting near-term market impact.

Analysis

A preclinical study in highly translatable non-human primate models found that selective PKA-II modulation combined with levodopa improved motor benefit while reducing dyskinesia. The results are encouraging for Parkinson’s symptom control, but no clinical or company-specific quantitative outcomes were provided, limiting near-term market impact.